Results 21 to 30 of about 3,591 (213)

Glycopyrrolate and formoterol fumarate for the treatment of COPD [PDF]

Expert Review of Respiratory Medicine, 2020
Long acting bronchodilators are nowadays the central treatment for management of stable COPD. Several combinations exist within the market with different formulation devices. This article reviews a recent dual combination of glycopyrronium and formoterol fumarate in an innovative pMDI-fixed dual combination, Bevespi® Aerosphere.This article explored ...
Grillet, Pierre-Edouard, Le Souder, Cosette, Rohou, Juliette, Cazorla, Olivier, Charriot, Jérémy, Bourdin, Arnaud   +5 more
openaire   +3 more sources

Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Respiratory Research, 2021
Background In the Phase III KRONOS study, triple therapy with budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) was shown to reduce exacerbations and improve lung function versus glycopyrronium/formoterol fumarate dihydrate ...
Shigeo Muro, Hisatoshi Sugiura, Patrick Darken, Paul Dorinsky   +3 more
doaj   +1 more source

COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA

Архивъ внутренней медицины, 2016
There were examined 86 patients aged 20 to 65 years with a diagnosis of bronchial asthma (BA). The objective is to evaluate the level of disease control, to study the effectiveness, safety and usability when used Foster (beclomethasone dipropionate and ...
V. A. Nikitin, O. A. Lepuchova, L. V. Vasilieva, E. P. Karpuchina   +3 more
doaj   +1 more source

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD : a systematic review and meta-analysis [PDF]

, 2017
Acknowledgments The meta-analysis work was performed by Guruprasad Rao KS and Sharanbasappa Durg of Molecular Connections (P) Ltd, Bangalore, India, under the guidance of the manuscript authors and Novartis Pharma AG (Basel, Switzerland). Medical writing
Altman, Pablo, Anzueto, Antonio, Bader, Giovanni, Fogel, Robert, Kostikas, Konstantinos, Patalano, Francesco, Price, David B, Rodrigo, Gustavo J, Singh, Dave   +8 more
core   +2 more sources

Regular treatment with formoterol for chronic asthma: serious adverse events [PDF]

, 2012
Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe ...
Altman, Blauw, Cates, Cates, Cates, Cates, Ducharme, Greenstone, Higgins, Lipworth, Nelson, Ni Chroinin, Ni Chroinin, Pearce, Pearce, Salpeter, Walters, Walters   +17 more
core   +1 more source

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD [PDF]

, 2017
The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 mug twice daily on lung hyperinflation ...
Beeh, Kai M., Garcia Gil, Esther, García Aymerich, Judith, Jarreta, Diana, Molins, Eduard, Notari, Massimo, Paggiaro, Pierluigi, Troosters, Thierry, Watz, Henrik, Zapata, Antonio   +9 more
core   +2 more sources

Economic Evaluation Of Fluticasone Propionate/Formoterol Fumarate (Flutiform®) Vs Fluticasone/Salmeterol And Budesonide/Formoterol In Spain [PDF]

Value in Health, 2015
Introduction The aim of this economic evaluation was to estimate the cost-effectiveness of fluticasone propionate/formoterol (FP/FORM; Flutiform®) and compare it to those of fluticasone/salmeterol (FS) and budesonide/formoterol (BF) when used in the treatment of adult patients with moderate-to-severe asthma.
Martínez-Moragón, E, Delgado, J, Ojeda, P, Pérez del Llano, L, Antón, C, Martín, C, Collar, JM   +6 more
openaire   +2 more sources

Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial

Therapeutic Advances in Respiratory Disease, 2008
Formoterol fumarate is a long-acting β 2-agonist that is an effective bronchodilator for the maintenance management of patients with chronic obstructive pulmonary disease.
James F. Donohue, Nicola A. Hanania, Charles Fogarty, Sammy C. Campbell, Mike Rinehart, Kimberly Denis-Mize   +5 more
doaj   +1 more source

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study [PDF]

, 2014
Background Aclidinium/formoterol is a twice-daily (BID) fixed-dose combination (FDC) in development for chronic obstructive pulmonary disease (COPD).
Anne Leselbaum, Cristina Serra, Cynthia Caracta, Dave Singh, Eduard Molins, Eric D Bateman, Esther Garcia Gil, Paul W Jones, Stephanie Korn   +8 more
core   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers, Aalbers, Altman, Barnes, Beach, Bleecker, Busse, Cates, Cates, Cates, Cates, Cates, Dahl, Ducharme, Ducharme, Ducharme, Giembycz, Higgins, Lasserson, Lipworth, Nelson, Ni Chroinin, Papi, Ringdal, Salpeter, Tamminen, Walters, Walters   +27 more
core   +2 more sources